Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Inclusion Criteria:

• Be willing and able to provide written informed consent for the study.
• Be ±18 years of age of either sex and of any race/ethnicity;
• Part 1: Have a histologically or cytologically confirmed advanced malignant solid tumor;
• Part 2: Have a histologically or cytologically confirmed, with measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]), advanced, malignant solid tumor.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of <=2.
• Have adequate organ function within 3 weeks prior to first study drug administration.

Exclusion Criteria:

• Not have known treated or untreated leptomeningeal metastasis or a metastatic central nervous system lesion.
• Not have a history of another malignancy
• Not have received prior therapy with any anti-insulin-like growth factor receptor 1 (anti-IGF-1R) monoclonal antibody.
• Not have received radiation therapy within 2 weeks prior to first study drug administration.
• Not have received radiation therapy to >25% of his/her total bone marrow during his/her lifetime.
• Not have undergone major surgery within 3 weeks prior to first study drug administration.
• Not have known human immunodeficiency virus (HIV) infection or a known HIV-related malignancy.
• Not have known active hepatitis B or C.
• Not have any serious or uncontrolled infection.
• Not have uncontrolled diabetes mellitus.
• Not have had any of the following within 6 months prior to first study drug administration: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, clinically significant cardiac dysrhythmia or clinically significant electrocardiogram (ECG) abnormality, cerebrovascular accident or transient ischemic attack, or seizure disorder.